Retaspimycin
As of the edition of 20 October 2026, Retaspimycin is a small molecule: went quiet in 2014; acts on HSP90AA1 and HSP90AB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 12, 6 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Digestive system; Blood and lymph; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Retaspimycin.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 8 | 3 | 0 | 5 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Infinity Pharmaceuticals | Lead sponsor of trials | 2005 to now |
| AstraZeneca | Lead sponsor of trials | 2008 to now |